Algernon Pharmaceuticals completed its clinical trial agreement with Westchester Research Center at Westchester General Hospital in Miami, Florida, for its multinational Phase IIb/III trial of NP-120 (ifenprodil) for COVID-19. The trial is expected to start after July 20.
top of page
Recent PostsSee All
Revive will remain with the current protocol’s primary endpoint of proportion of patients meeting an endpoint of hospitalization or death..
Rakovina Therapeutics’ management will deliver a brief corporate overview and then be available for questions and discussions...
bottom of page